Literature DB >> 21251645

Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine.

Noemí Santana1, Eva Troyano-Rodriguez, Guadalupe Mengod, Pau Celada, Francesc Artigas.   

Abstract

BACKGROUND: Noncompetitive N-methyl-D-aspartate receptor antagonists are widely used as pharmacological models of schizophrenia. Their neurobiological actions are still poorly understood, although the prefrontal cortex (PFC) appears as a key target area.
METHODS: We examined the effect of phencyclidine (PCP) on neuronal activity of the mediodorsal (MD) and centromedial (CM) thalamic nuclei, reciprocally connected with the PFC, using extracellular recordings (n = 50 neurons from 35 Wistar rats) and c-fos expression.
RESULTS: Phencyclidine (.25 mg/kg intravenous [IV]) markedly disorganized the activity of MD/CM neurons, increasing (424%) and decreasing (41%) the activity of 57% and 20% of the recorded neurons, respectively (23% remained unaffected). Phencyclidine reduced delta oscillations (.15-4 Hz) as assessed by recording local field potentials. The subsequent clozapine administration (1 mg/kg IV) reversed PCP effects on neuronal discharge and delta oscillations. Double in situ hybridization experiments revealed that PCP (10 mg/kg intraperitoneal [IP]) markedly increased c-fos expression in glutamatergic neurons of several cortical areas (prefrontal, somatosensory, retrosplenial, entorhinal) and in thalamic nuclei, including MD/CM. Phencyclidine also increased c-fos expression in the amygdala; yet, it had a small effect in the hippocampus. Phencyclidine did not increase c-fos expression in gamma-aminobutyric acidergic cells except in hippocampus, amygdala, somatosensory, and retrosplenial cortices. Clozapine (5 mg/kg IP) had no effect by itself but significantly prevented PCP-induced c-fos expression.
CONCLUSIONS: Phencyclidine likely exerts its psychotomimetic action by increasing excitatory neurotransmission in thalamo-cortico-thalamic networks involving, among others, PFC, retrosplenial, and somatosensory cortices. The antipsychotic action of clozapine includes, among other actions, an attenuation of the neuronal hyperactivity in thalamocortical networks.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251645     DOI: 10.1016/j.biopsych.2010.10.030

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  28 in total

1.  Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.

Authors:  Lucila Kargieman; Maurizio S Riga; Francesc Artigas; Pau Celada
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

Review 2.  Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.

Authors:  Michael J Gandal; J Christopher Edgar; Kerstin Klook; Steven J Siegel
Journal:  Neuropharmacology       Date:  2011-02-22       Impact factor: 5.250

3.  Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.

Authors:  Francesc Artigas; Esther Schenker; Pau Celada; Michael Spedding; Laia Lladó-Pelfort; Noemi Jurado; Mercedes Núñez; Noemi Santana; Eva Troyano-Rodriguez; Maurizio S Riga; Hanna van den Munkhof; Anna Castañé; Hamdy Shaban; Thérèse M Jay; Anushree Tripathi; Bill P Godsil; Claude Sebban; Jean Mariani; Philippe Faure; Samir Takkilah; Zoe A Hughes; Chester J Siok; Mihaily Hajos; Karsten Wicke; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Robert Becker; Michael Didriksen; Jesper F Bastlund; Mark Tricklebank; Céline Risterucci; Andreas Meyer-Lindenberg; Adam J Schwarz
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

4.  Sleep in patients with schizophrenia.

Authors:  Fabio Ferrarelli
Journal:  Curr Sleep Med Rep       Date:  2015-04-11

Review 5.  Brain rhythms connect impaired inhibition to altered cognition in schizophrenia.

Authors:  Benjamin R Pittman-Polletta; Bernat Kocsis; Sujith Vijayan; Miles A Whittington; Nancy J Kopell
Journal:  Biol Psychiatry       Date:  2015-02-14       Impact factor: 13.382

6.  PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.

Authors:  Anna Castañé; Noemí Santana; Francesc Artigas
Journal:  Psychopharmacology (Berl)       Date:  2015-05-07       Impact factor: 4.530

7.  Reduced mediodorsal thalamic volume and prefrontal cortical spindle activity in schizophrenia.

Authors:  Andreas Buchmann; Daniela Dentico; Michael J Peterson; Brady A Riedner; Simone Sarasso; Marcello Massimini; Giulio Tononi; Fabio Ferrarelli
Journal:  Neuroimage       Date:  2014-08-17       Impact factor: 6.556

8.  Afferent drive of medial prefrontal cortex by hippocampus and amygdala is altered in MAM-treated rats: evidence for interneuron dysfunction.

Authors:  Behnaz Esmaeili; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-03-07       Impact factor: 7.853

9.  The electrophysiological signature of motivational salience in mice and implications for schizophrenia.

Authors:  Carolin Moessnang; Ute Habel; Frank Schneider; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2012-08-22       Impact factor: 7.853

Review 10.  Reduced sleep spindle activity point to a TRN-MD thalamus-PFC circuit dysfunction in schizophrenia.

Authors:  Fabio Ferrarelli; Giulio Tononi
Journal:  Schizophr Res       Date:  2016-06-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.